ATE448230T1 - Für die behandlung von obesitas geeignete tricyclische amidderivate - Google Patents
Für die behandlung von obesitas geeignete tricyclische amidderivateInfo
- Publication number
- ATE448230T1 ATE448230T1 AT06819827T AT06819827T ATE448230T1 AT E448230 T1 ATE448230 T1 AT E448230T1 AT 06819827 T AT06819827 T AT 06819827T AT 06819827 T AT06819827 T AT 06819827T AT E448230 T1 ATE448230 T1 AT E448230T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- obesitas
- amide derivatives
- derivatives suitable
- tricyclic amide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05111879 | 2005-12-09 | ||
PCT/EP2006/069040 WO2007065820A1 (en) | 2005-12-09 | 2006-11-29 | Tricyclic amide derivatives useful for treating obesity |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE448230T1 true ATE448230T1 (de) | 2009-11-15 |
Family
ID=37728185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06819827T ATE448230T1 (de) | 2005-12-09 | 2006-11-29 | Für die behandlung von obesitas geeignete tricyclische amidderivate |
Country Status (13)
Country | Link |
---|---|
US (2) | US7579351B2 (de) |
EP (1) | EP1960401B1 (de) |
JP (1) | JP2009518351A (de) |
KR (1) | KR20080085014A (de) |
CN (1) | CN101321761A (de) |
AT (1) | ATE448230T1 (de) |
AU (1) | AU2006324089A1 (de) |
BR (1) | BRPI0619597A2 (de) |
CA (1) | CA2631128A1 (de) |
DE (1) | DE602006010433D1 (de) |
ES (1) | ES2333672T3 (de) |
IL (1) | IL191629A0 (de) |
WO (1) | WO2007065820A1 (de) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2009038974A1 (en) * | 2007-09-20 | 2009-03-26 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
EP2254886B1 (de) | 2008-03-28 | 2016-05-25 | Nerviano Medical Sciences S.r.l. | 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-on derivate als kinase inhibitoren, verfahren zu deren herstellung und diese enthaltende pharmazeutische zubereitungen |
CN102388043A (zh) * | 2009-02-11 | 2012-03-21 | 桑诺维恩药品公司 | 组胺h3反相激动剂和拮抗剂及其使用方法 |
JP2013504581A (ja) * | 2009-09-11 | 2013-02-07 | スノヴィオン ファーマシューティカルズ インコーポレイテッド | ヒスタミンh3インバースアゴニストおよびアンタゴニストとその使用方法 |
EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
MX354820B (es) | 2012-03-16 | 2018-03-21 | Vitae Pharmaceuticals Inc | Moduladores del receptor x del higado. |
WO2013138565A1 (en) | 2012-03-16 | 2013-09-19 | Vitae Pharmaceuticals, Inc. | Liver x receptor modulators |
EP2831080B1 (de) * | 2012-03-29 | 2017-03-15 | Francis Xavier Tavares | Lactamkinaseinhibitoren |
EP2880036B1 (de) * | 2012-08-06 | 2017-03-08 | F. Hoffmann-La Roche AG | Piperazin[1,2-a-]indol-1-one und [1,4-]diazepin[1,2-a-]indol-1-on |
CN102924459B (zh) * | 2012-10-25 | 2015-04-08 | 华东师范大学 | 吡咯稠环3-吲哚酮类化合物的合成方法 |
JP6435315B2 (ja) | 2013-03-15 | 2018-12-05 | ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. | 高活性抗新生物薬及び抗増殖剤 |
PT2968290T (pt) | 2013-03-15 | 2019-11-27 | G1 Therapeutics Inc | Protecção transitória de células normais durante a quimioterapia |
JP6212623B2 (ja) | 2013-04-02 | 2017-10-11 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ピペラジノ[1,2−a]インドール−1−オン及び[1,4]ジアゼピノ[1,2−a]インドール−1−オン |
WO2015161287A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use in the protection of normal cells during chemotherapy |
EP3191098A4 (de) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Kombinationen und dosierschemen zur behandlung von rb-positiven tumoren |
WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
US10487087B2 (en) | 2015-12-30 | 2019-11-26 | Vanderbilt University | Positive allosteric modulators of the GLP-1 receptor |
US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
US5246960A (en) | 1984-12-21 | 1993-09-21 | Hoffmann-La Roche Inc. | Oxetanones |
CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
CA2035972C (en) | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
EP0572863A1 (de) | 1992-06-05 | 1993-12-08 | F. Hoffmann-La Roche Ag | ZNS Pyrazinoindole |
US5404967A (en) * | 1993-05-14 | 1995-04-11 | Barry; Hubert M. | Extruding device |
EP0639573A1 (de) | 1993-08-03 | 1995-02-22 | Hoechst Aktiengesellschaft | Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament |
US5405967A (en) * | 1993-10-22 | 1995-04-11 | Oklahoma Medical Research Foundation | Spin-trap molecules 2-trifluoromethyl- of 5,5-dimethyl-1-dyrroline-N-oxide |
JP4272261B2 (ja) | 1996-12-10 | 2009-06-03 | アボツト・ラボラトリーズ | 3−ピリジルエナンチオマーおよび鎮痛薬としてのその使用 |
US6004996A (en) | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
BR9912980B1 (pt) | 1998-08-14 | 2013-10-22 | Composição farmacêutica administrável oralmente, tablete de mascar contendo a mesma e utilização da mesma | |
WO2000009123A1 (en) | 1998-08-14 | 2000-02-24 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions containing lipase inhibitors and chitosan |
GB9902461D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
MXPA01009814A (es) | 1999-03-29 | 2002-04-24 | Hoffmann La Roche | Activadores de la glucoquinasa. |
GB0000626D0 (en) | 2000-01-13 | 2000-03-01 | Zeneca Ltd | Chemical compounds |
KR100539139B1 (ko) | 2000-07-31 | 2005-12-26 | 에프. 호프만-라 로슈 아게 | 피페라진 유도체 |
CA2432085C (en) | 2000-12-27 | 2009-02-24 | F. Hoffmann-La Roche Ag | Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands |
GB0106177D0 (en) * | 2001-03-13 | 2001-05-02 | Hoffmann La Roche | Piperazine derivatives |
US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
GB0202015D0 (en) * | 2002-01-29 | 2002-03-13 | Hoffmann La Roche | Piperazine Derivatives |
EP1585731A2 (de) * | 2002-09-18 | 2005-10-19 | Eli Lilly And Company | Histamin h3 rezeptor-antagonisten, herstellung und therapeutische verwendung |
GB0314967D0 (en) * | 2003-06-26 | 2003-07-30 | Hoffmann La Roche | Piperazine derivatives |
-
2006
- 2006-11-29 ES ES06819827T patent/ES2333672T3/es active Active
- 2006-11-29 CN CNA2006800455782A patent/CN101321761A/zh active Pending
- 2006-11-29 WO PCT/EP2006/069040 patent/WO2007065820A1/en active Application Filing
- 2006-11-29 JP JP2008543776A patent/JP2009518351A/ja active Pending
- 2006-11-29 US US11/605,899 patent/US7579351B2/en not_active Expired - Fee Related
- 2006-11-29 CA CA002631128A patent/CA2631128A1/en not_active Abandoned
- 2006-11-29 KR KR1020087016597A patent/KR20080085014A/ko active IP Right Grant
- 2006-11-29 AT AT06819827T patent/ATE448230T1/de active
- 2006-11-29 BR BRPI0619597-0A patent/BRPI0619597A2/pt not_active IP Right Cessation
- 2006-11-29 DE DE602006010433T patent/DE602006010433D1/de active Active
- 2006-11-29 EP EP06819827A patent/EP1960401B1/de not_active Not-in-force
- 2006-11-29 AU AU2006324089A patent/AU2006324089A1/en not_active Abandoned
-
2008
- 2008-05-22 IL IL191629A patent/IL191629A0/en unknown
-
2009
- 2009-02-20 US US12/389,619 patent/US7786109B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2009518351A (ja) | 2009-05-07 |
AU2006324089A1 (en) | 2007-06-14 |
ES2333672T3 (es) | 2010-02-25 |
US7786109B2 (en) | 2010-08-31 |
IL191629A0 (en) | 2008-12-29 |
CN101321761A (zh) | 2008-12-10 |
KR20080085014A (ko) | 2008-09-22 |
WO2007065820A1 (en) | 2007-06-14 |
EP1960401A1 (de) | 2008-08-27 |
EP1960401B1 (de) | 2009-11-11 |
US7579351B2 (en) | 2009-08-25 |
BRPI0619597A2 (pt) | 2011-10-04 |
US20090156583A1 (en) | 2009-06-18 |
CA2631128A1 (en) | 2007-06-14 |
DE602006010433D1 (de) | 2009-12-24 |
US20070135416A1 (en) | 2007-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE448230T1 (de) | Für die behandlung von obesitas geeignete tricyclische amidderivate | |
WO2007062999A3 (en) | 1,5-substituted indol-2-yl amide derivatives | |
DE602006010738D1 (de) | Pyrroloä2,3-cüpyridinderivate | |
NO20082096L (no) | Azaindol-2-karboksamidderivativer | |
EA201000050A1 (ru) | Замещенные бициклолактамные соединения | |
GB0510141D0 (en) | Novel compounds B3 | |
UY28774A1 (es) | Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes. | |
EA201070422A1 (ru) | Производные оксадиазола | |
EA200601295A1 (ru) | Производные 1,3-диоксана и их аналоги, применимые для лечения i.a. ожирения и диабета | |
MA32505B1 (fr) | 5-alcynyl-pyrimidines | |
EA201000395A1 (ru) | Фунгицидные производные 2-алкилтио-2-хинолинилоксиацетамида | |
MX2008013196A (es) | 5-amido-2-carboxiamida-indoles. | |
ATE536354T1 (de) | Neuartige 1-aza-bizykloalkyl-derivate für die behandlung psychotischer und neurodegenerativer störungen | |
GB0508318D0 (en) | Organic compounds | |
MY151348A (en) | Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | |
DE502005008057D1 (de) | Substituierte cyclopenten-verbindungen | |
ATE467632T1 (de) | Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors | |
DE602006009789D1 (de) | Acetylenderivate | |
DK2212282T3 (da) | Substituerede N-phenylbipyrrolidincarboxamider og terapeutisk anvendelse deraf | |
DK2215058T3 (da) | Substituerede N-phenylbipyrrolidinureaer og terapeutisk anvendelse deraf | |
TW200738651A (en) | Cyclohexyl sulfonamide derivatives | |
NO20071254L (no) | Fremgangsmate for fremstilling av irbesartan og mellomprodukter derav. | |
MA32943B1 (fr) | Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique | |
CY1109569T1 (el) | Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης | |
TW200716564A (en) | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1960401 Country of ref document: EP |